Zensun Sci & Tech

Executive Summary

Zensun Sci & Tech is a private, pre-clinical biopharmaceutical company founded in 2001, with R&D headquarters in Shanghai and a US office in San Diego. The company focuses on developing first-in-class biologic and small molecule therapeutics for serious life-threatening conditions with unmet medical needs, particularly heart failure. Leveraging deep expertise in cell signaling and energy metabolism, Zensun has built a proprietary platform targeting novel cardiomyocyte therapies. Despite over two decades of research, the company remains in the pre-clinical stage, with no disclosed pipeline, funding, or partnerships. The absence of public catalysts or recent news suggests a long development timeline and high risk.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Heart Failure Program20% success
• Q2 2026Publication of Preclinical Efficacy Data in Peer-Reviewed Journal40% success
• Q4 2026Announcement of Strategic Partnership or Licensing Deal15% success